Publications by authors named "Sanjeev Deva"

Claim this Profile
S
Single-Agent Divarasib in Patients With -Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Adrian G Sacher, Wilson H Miller, Manish R Patel, Luis Paz-Ares, Armando Santoro, Sanjeev Deva

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.
Jayesh Desai, Sanjeev Deva, Bo Gao, Kunyu Yang, Kenneth J O'Byrne

Cancer Chemother Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity.
Nuala Helsby, Katrina Sharples, Yu Jin Kim, David Porter, Kathryn Burns, Sanjeev Deva

Cancer Chemother Pharmacol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent mutant colorectal cancer.
Sara Roth, Kasmira Claire Wilson, Robert George Ramsay, Catherine Mitchell, Shienny Sampurno, Sanjeev Deva

Heliyon· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Sanjeev Deva

EBioMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blending space and time to talk about cancer in extended reality.
Tamsin J Robb, Yinan Liu, Braden Woodhouse, Charlotta Windahl, Daniel Hurley, Sanjeev Deva

NPJ Digit Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Sanjeev Deva

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Nadia Hitchen, Nick R Waldron, Sanjeev Deva, Michael Findlay, Benjamin Lawrence

Asia Pac J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.
Khanh B Tran, Sharada Kolekar, Qian Wang, Jen-Hsing Shih, Christina M Buchanan, Sanjeev Deva

Mol Cancer Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
Zhihao Lu, Silu Yang, Xuerui Luo, Yang Shi, Jong-Seok Lee, Sanjeev Deva

Gastric Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.
Jimmy He, Christopher G C A Jackson, Sanjeev Deva, Tak Hung, Katriona Clarke

CPT Pharmacometrics Syst Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
Ezra E W Cohen, Lisle Nabell, Deborah J Wong, Terry Day, Gregory A Daniels, Sanjeev Deva

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
Christopher G C A Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Sanjeev Deva

Br J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Troponin I and T in Checkpoint Inhibitor-associated Myositis and Myocarditis.
Edmond Ang, Angela Mweempwa, Campbell Heron, Yeri Ahn, Gareth Rivalland, Sanjeev Deva

J Immunother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, Chia-Chi Lin, Chia-Jui Yen

J Immunother Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care.
Michelle Wilson, Weng Mak, Melissa Firth, Sanjeev Deva, Michael Findlay

N Z Med J· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
Reuben J Broom, Victoria Hinder, Katrina Sharples, Janie Proctor, Steven Duffey, Sanjeev Deva

Clin Genitourin Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Christopher G C A Jackson, Katrina Sharples, Paul I Thompson, Anne O'Donnell, Bridget Anne Robinson, Sanjeev Deva

BMC Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status.
Reuben J Broom, Imogen Caldwell, Fritha Hanning, Peter Fong, Sanjeev Deva

Clin Genitourin Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.
Sanjeev Deva, Michael Jameson

Cochrane Database Syst Rev· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis